Ocular Therapeutix has announced positive topline results from the SOL-1 Phase III superiority trial of Axpaxli—also known as ...

Italian pharma major Recordati has reported 2025 revenues of 2.62 billion euros ($3.1 billion), which was in line with ...

US mRNA specialist Moderna today announced that, in response to a prior Refusal-to-File (RTF) letter, the company engaged ...

Swiss biotech NewBiologix, which is advancing recombinant adeno-associated virus (rAAV) production through next-generation ...

Switzerland-based generic and biosimilar drugs specialist Sandoz today announced that the US Food and Drug Administration ...

Swiss pharma giant Novartis has announced positive topline results from its pivotal Phase III RemIND trial of oral remibrutinib in chronic inducible urticaria (CIndU).

California biotech Unnatural Products (UNP), which is developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced a research collaboration and licensing ...

USA based Korsana Biosciences, which is developing novel therapies to reduce the burden of neurodegenerative diseases, today announced its emergence from stealth, with backing from a leading syndicate ...

Australian biotech CSL Limited has entered into an exclusive licensing agreement with US pharma major Eli Lilly granting the latter certain rights to develop and commercialize clazakizumab, an ...

Rare Disease Day on February 28, highlights the persistent challenges of developing treatments for conditions where patient numbers are small and data is scarce. Confidence in clinical development is ...

US late-stage biotech Immunic (Nasdaq: IMUX) yesterday announced the closing of its private placement financing.

Compass Pathways has announced the successful achievement of the primary endpoint in the ongoing Phase III COMP006 trial, the ...